THE ROLE OF ADIPONECTIN IN THE DEVELOPMENT AND PROGRESSION OF METABOLIC SYNDROME
Keywords:
biologically active, increase in cholesterol, smooth muscle.Abstract
Metabolic syndrome (MS) is a complex interrelated pathogenetic symptoms and metabolic disorders that increase the risk of developing atherosclerosis and coronary heart disease (CHD) among which highlight violations such as obesity and/or abdominal fat distribution, insulin resistance (IR), atherogenic dyslipidemia, arterial hypertension (AH), hyperuricemia, and several other manifestations [2,3,5].
References
Saginova E. A., Galyamov M. G., Severova M. M. et al. The role of leptin, adiponectin, and insulin resistance markers in the development of early stages of chronic kidney disease and carotid artery atherosclerosis in obese patients. Ter. archive. 2011;6:47-53
Tanyansky D. A., Firova E. M., Shatilina L. V. et al. Adiponectin: reduced levels in metabolic syndrome and independent association with hypertriglyceridemia. Cardiology. 2008;12:20-25.
Chibisova S. M., Rapoport S. I., Kolesnikov D. B. et al. Metabolic syndrome: more questions than answers. A wedge. the medicine. 2006;6:30-34.
Abbasi F., Chu J., Lamendola C. et al. Discrimination betveen obesity and insulin resistance in the relationship with adiponektin. Diabetes. 2004;53:585-590.
ACE position statement on the insulin resistance syndrome. Endocr. Pract. 2003;9:240-252.
Adamezak M., Wiecek A., Funahashi T. et al. Decreased plasma adiponektin concentration in patients with essential hypertension. Am. J. Hypertens. 2003;16:72-75.
Bruun J., Lihn A., Verdich C. et al. Regulation of adipenectin by adipose tissue-derived cytokines: in vivo and vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 2003;285:Е527-Е533.
Das U. Is metabolic syndrome X an inflammatory condition? Exp. Biol. Med. 2002;227:989-997.
Executive Summary of the Third of the National Cholesterol Education Program (NCEP) expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-2497.
Lihn A., Ostergard T., Nyholm B. et.al. Adiponection expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am. Physiol. Endocrinol. Metab. 2003;284:E443-E448.
Matsubara M., Katayose S., Maruoke S. Decreased plasma adiponectin concentration in nondiabetic women with elevated homeostasis model assessment ratios. Eur. J. Endocrinol. 2003;148:343-350.
Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vask. Biol. 2004;24:29-33.
Schulze M., Rimm E., Shai I. et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Care. 2004;27:1680-1687.
Weyer C., Funahashi T., Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetis: close assоciation with insulin resistence and hyperinsulinemia. J. Clin. Endocrinal. Metab. 2001;86:1930-1935.
Yamauchi T., Camon J., Minokpshi Y. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002;811:1288-1295
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 GEJournals
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
